Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PBT-1 Prana Biotechnology.

Richard Huckle1

  • 1Axovan Ltd, Innovation Center, Allschwil, Switzerland. richard@huckle2.fsbusiness.co.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|January 29, 2005
PubMed
Summary

Prana Biotechnology

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting.

Journal of neurodevelopmental disorders·2026
Same author

Gaboxadol. Lundbeck/Merck.

Current opinion in investigational drugs (London, England : 2000)·2004
Same author

Pregabalin (Pfizer).

Current opinion in investigational drugs (London, England : 2000)·2004
Same author

Lerisetron. FAES.

Current opinion in investigational drugs (London, England : 2000)·2003

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Alzheimer's disease is a progressive neurodegenerative disorder.
  • Current treatments offer limited efficacy.

Purpose of the Study:

  • To evaluate the potential of PBT-1 (clioquinol) as a treatment for Alzheimer's disease.

Main Methods:

  • Phase II clinical trials were conducted.
  • Phase III trials were planned for early 2005.

Main Results:

  • PBT-1 (clioquinol) is undergoing clinical evaluation for Alzheimer's disease treatment.

Conclusions:

  • Further clinical trials are planned to assess PBT-1's efficacy and safety.